The anticancer effect of β-Lap has been associated with the downregulation of mutant p53 in SW480 human colon cancer cells, and it has also occurred in human colon cancer cells (HCT116, wild-type p53; SW620, mutant p53; DLD1, defective p53) and human prostate cancer cells (LNCaP, wild-type p53; DU-145, mutant p53; PC-3, null-type p53), regardless of p53 status, by inducing cell cycle arrest and apoptosis [4,5,6]. Here, TP53 is linked to prostate carcinoma.